LK Hyman
02 Dec 2014
Re: Why the rise? Pharma,"the inheritance tax exemption on holdings in AIM companies after they have been owned for for two years or more is very attractive."I can quite understand that attitude, though it has always struck me as dangerous for investors when government provides generous tax breaks merely for holding Investment A (AIM) but not for holding Investment B (Main Market). That's a charlatan's charter. As an aside, it also strikes me as totally wrong that people who would normally be liable for IHT should be able to avoid it via the simple expedient of slapping their wad (or part of it) into an AIM company. Yeah, yeah, I know that government wants to encourage investment in small companies, but that ain't the way to do it. Rant over.If I were Gidiot I'd abolish IHT completely and, when someone carks it, I'd tax whatever his/her heirs received in the will at his/her marginal income tax rate. It's right that recipients of largesse pay tax on the spondoolies, but not right that, in addition to the disappointment of actually dying, one's estate is then stripped by HMRC.LKH on the flybridge
Eating Grass
02 Dec 2014
Abcam moving from AIM to the main LSE market? If Abcam moves to the main stock market I am sure the share price would quickly rise with the higher profile. Abcam could raise cheaper money and grow more quickly with more frequent or bigger acquisitions. On the downside it would cost Abcam more in accountancy and broker fees to prepare for the transition. So should Abcam join the big boys?In the short term we shareholders would do very well. Yet there is no immediate imperative because Abcam is already cash rich and does not need external funding for organic growth. Abcam is already big enough to move from AIM having a market cap of over £850 million.In the long run a massive Abcam which would be like "Amazon for Biological Consumable". A bigger portfolio of trusted reagents might be very handy for scientists. If Abcam does go on the take over trail this could happen any time (and make LK Hyman happy). Perhaps I should hang onto my shares until after Abcam joins the main market - it is just a question of when the inevitable happens.
pharmaspecialist
02 Dec 2014
Re: Why the rise? I agree with most of what you say LKH but I very much hope that Abcam does not move to the main market as I am a long term investor and the inheritance tax exemption on holdings in AIM companies after they have been owned for for two years or more is very attractive. No doubt this is also attractive to some of Abcam's large shareholders, including some directors. This is also why quite a few family owned companies are on AIM and I have noticed that some of these companies, where the family owns large stakes, seem to be quite good quality companies with decent long term records.
LK Hyman
02 Dec 2014
Re: Why the rise? EG,And I like any business where the directors have a lot of skin in the game, as they do here, albeit not as much as in another of my top of the pops, Renishaw (RSW), where I have a bigger chunk of my shrunken wad invested than I do with Abcam.I'd like to see Abcam move to the main market ... I don't trust AIM companies as a general rule. The mere existence of a company on the AIM register is usually enough for me to put my cheque book back in its unborn baby crocodile skin wallet. Abcam is the one exception in my tiny portfolio.LKH on the flybridge
Eating Grass
02 Dec 2014
Re: Why the rise? I agree with Moonowl.Patience pays when looking at a pale grey box with scrolling news.We are informed the catalogue has 137,038 reagents and antibodies and also sales are over 140,000 items shipped.I am not sure what shipped means - maybe just stocking the shelves of the new warehouse in China !However I have confidence in Abcam who have shown great determination in achieving long term growth.This is an exiting business on the frontiers of biological science and not a boring mature enterprise as iii previously suggested. I personally like any business where management usually under promises and over delivers.
moonowl
01 Dec 2014
Re: Why the rise? Oh, so "shipped" means something else if it's in a grey box. I wasn't aware of this. Probably worth you looking again KM - it is very clearly stated.
KestleMill
01 Dec 2014
Re: Why the rise? The number listed in the grey box is not the number of products shipped, it is the number of products available on the catalogue. More products listed is likely to result in more sales and this number going up is definitely a good thing. I just wanted to clarify for you and others. I'm not sure why the share price has gone up - perhaps the new CEO has done a good job selling the story to institutional investors.
moonowl
29 Nov 2014
Re: Why the rise? Also, Goldman Sachs have just added it to their conviction buy list with a target price of 645p.Probably just means they've got a big line to unload, mind.
moonowl
24 Nov 2014
Re: Why the rise? Home page: there's a grey box half way down the right hand side which updates various pieces of information every few seconds - it will come up there. Still showing 140k.In January it was showing 110k. So, seems growth has stepped up a notch - justifying the slightly racy rating here.
Eating Grass
24 Nov 2014
Re: Why the rise? This is a great riposte to the recent curious iii article. I thought I knew the abcam website. Which page or section shows the number of shipments?
moonowl
24 Nov 2014
Re: Why the rise? Hi Kilindidnitheir website states how many products they've shipped over the last 90 days. Last week it rose from over 130k to over 140k. It was 110k at the start of the year. Clearly, they're trading well at the moment.
kilindidni
24 Nov 2014
Why the rise? Sudden move upwards without any obvious reason? Anyone have a view?
